PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Eladocagene Exuparvovec→

Eladocagene Exuparvovec PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
2098615-91-7
Molecular formula
Not available
Molecular weight
Not available
Drug class
Adeno-associated virus serotype 2 (AAV2) gene therapy delivering the DDC gene
Mechanism of action
A recombinant AAV2 vector delivers a functional copy of the DDC gene encoding aromatic L-amino acid decarboxylase (AADC) to cells in the putamen. The transduced cells produce AADC, supporting conversion of L-DOPA to dopamine in patients with AADC deficiency.
Indications / reported uses
  • Treatment of adult and paediatric patients with aromatic L-amino acid decarboxylase (AADC) deficiency under the applicable product authorisation; age criteria and specialist administration requirements are label-specific

Sources: US DailyMed — KEBILIDI (eladocagene exuparvovec) · US FDA product information — KEBILIDI · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Eladocagene Exuparvovec PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Eladocagene Exuparvovec Permitted Daily Exposure (PDE) report (the Eladocagene Exuparvovec PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Eladocagene Exuparvovec Occupational Exposure Limit (OEL) report (the Eladocagene Exuparvovec OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.